11 Australian biotech companies — 5 of them formed with Proto Axiom as founding investor. Sourced from 8 research institutions and health partners. 3 are clinical-stage companies.
A clinical-stage biotechnology company developing investigational oral insulin using enzyme-responsive, liver-targeting nanotechnology. Phase 1a first-in-human dosing has commenced.
“Oral insulin in human trials. Phase 1a dosing commenced September 2026.”
A deep‑tech genomics company developing a next‑generation DNA sequencing platform based on plasmonic nanoantenna technology — true single‑molecule sequencing without the traditional trade‑offs between accuracy, read length, cost and speed.
“A new way to read the molecule. Built in Sydney.”
A next‑generation topical antifungal for onychomycosis — combining the safety of topical therapy with efficacy approaching oral drugs, via a novel lyotropic liquid crystal drug‑delivery system.
“Phase IIb under way. Topical efficacy, oral-grade results.”
A platform biotechnology company developing NAD+ technologies to modulate cellular energy, metabolism and ageing biology — with IVF laboratory media as the lead clinical and commercial application.
“Better embryos, by way of cellular energy.”
A bioprocessing technology company developing novel downstream purification materials and workflows that improve the efficiency, cost and scalability of biologics manufacturing.
“A bottleneck in biologics, addressed onshore.”
Clinical‑stage radiopharmaceutical company developing targeted alpha therapies using lead‑212 (²¹²Pb) for cancers with poor existing standards of care.
“80% PSA50 response. ESMO 2025.”
A desktop RNA printer enabling rapid, distributed production of RNA for research and rare‑disease therapeutic applications.
“RNA, on demand, at the bench.”
A novel biomanufacturing platform — initially focused on human‑health compounds, now leading with an AI soil‑microbe product to reduce reliance on imported fertilisers.
“Sovereign fertiliser, made by microbes.”
A TGA-cleared at-home anorectal biofeedback device and clinician dashboard, bringing hospital-grade treatment for functional bowel disorders into the home.
“Hospital-grade bowel therapy, delivered at home.”
A gut-health platform building non-GMO next-generation biotics — with an initial consumer product targeting alcohol metabolism.
“Gut health first. Consumer biotics next.”
A biotechnology company developing programmable RNA-sensing platforms for next-generation therapeutics and diagnostics.
“RNA signals, precise responses.”
University of Sydney, UNSW Sydney, Monash University, Griffith University, Western Sydney University, Queensland University of Technology, ANZAC Research Institute, Sydney Local Health District.
Researcher with a translational program?
Explore Challenger Pitch for Health →